^
    13d
    All-trans retinoic acid combined with the VAH regimen for EVI1-positive acute myeloid leukemia: a case report with a brief literature review. (PubMed, Front Oncol)
    We report a case of a 42-year-old patient with EVI1-positive AML harboring the MLL-AF6 fusion gene, who failed to achieve remission after undergoing standard "IA" induction therapy and was then treated with VAH (venetoclax, azacitidine, and homoharringtonine) consolidation chemotherapy. This case suggests that the combination of ATRA with the VAH regimen may demonstrate promising efficacy and an acceptable safety profile in patients with EVI1-positive AML who are refractory to conventional chemotherapy. However, further clinical studies are required to confirm its wider applicability.
    Journal
    |
    AFDN (Afadin, Adherens Junction Formation Factor)
    |
    Venclexta (venetoclax) • azacitidine • Synribo (omacetaxine mepesuccinate)
    15d
    Gossypol Inhibits GLI3-dependent SHH Signaling to Selectively Target SPOP-deficient Breast Cancer Cells. (PubMed, Anticancer Res)
    These findings identify a novel oncogenic role for SPOP loss in promoting breast cancer progression via GLI3-dependent SHH signaling. Furthermore, gossypol is highlighted as a potential targeted therapeutic agent for breast cancers characterized by SPOP deficiency.
    Journal
    |
    SPOP (Speckle Type BTB/POZ Protein) • GLI3 (GLI Family Zinc Finger 3)
    |
    R-(-)-gossypol (AT 101)
    21d
    Single-Center Prospective Study of Homoharringtonine Combined with Azacitidine and Venetoclax in the Treatment of Adult Patients with Newly Diagnosed Acute Myeloid Leukemia (ChiCTR2600120015)
    P=N/A, N=60, The First Hospital of China Medical University; The First Hospital of China Medical University
    New trial
    |
    Venclexta (venetoclax) • sorafenib • Xospata (gilteritinib) • azacitidine • Synribo (omacetaxine mepesuccinate)
    27d
    XPO1 inhibitor KPT-330 disrupts the core transcriptional regulatory circuitry of dedifferentiated liposarcoma by modulating the translation process. (PubMed, Oncogene)
    Furthermore, we identify a synergistic antitumor effect between KPT-330 and translation inhibitors, including everolimus and homoharringtonine. Notably, the disruptive impact of KPT-330 on CRC homeostasis extends to other cancer cell lineages, underscoring its broad mechanistic relevance. Collectively, our findings elucidate a novel mechanism through which KPT-330 destabilizes CRC via translational dysregulation and highlight its potential therapeutic utility in combination regimens for DDLPS.
    Journal
    |
    XPO1 (Exportin 1)
    |
    everolimus • Xpovio (selinexor) • Synribo (omacetaxine mepesuccinate)
    1m
    Safety and Efficacy of Docetaxel, Darolutamide, and Homoharringtonine Combined With Androgen Deprivation Therapy in Neoadjuvant Treatment of High-Risk Prostate Cancer: A Multicenter Prospective, Single-Arm Clinical Study (clinicaltrials.gov)
    P1, N=94, Not yet recruiting, Zhongda Hospital
    New P1 trial
    |
    docetaxel • Nubeqa (darolutamide) • goserelin acetate • Synribo (omacetaxine mepesuccinate)
    1m
    HVA-MPAL: HVA in the Treatment of Mixed-Phenotype Acute Leukemia(MPAL). (clinicaltrials.gov)
    P2, N=40, Enrolling by invitation, Guangdong Second Provincial General Hospital
    New P2 trial
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Venclexta (venetoclax) • azacitidine • Synribo (omacetaxine mepesuccinate)
    1m
    Quizartinib and omacetaxine mepesuccinate combination therapy in FLT3-ITD AML: a phase II trial. (PubMed, Nat Commun)
    PLD1-inhibitor remodeled phospholipid metabolism, induced ferroptosis and restored QUIZOM response in LSC. Our findings provided the therapeutic and resistant mechanisms of QUIZOM and paved the way for targeted interventions in this AML subtype.
    P2 data • Journal
    |
    FLT3 (Fms-related tyrosine kinase 3) • NPM1 (Nucleophosmin 1) • DNMT3A (DNA methyltransferase 1) • CD8 (cluster of differentiation 8) • WT1 (WT1 Transcription Factor)
    |
    NPM1 mutation
    |
    Vanflyta (quizartinib) • Synribo (omacetaxine mepesuccinate)
    1m
    Exploratory Study of Venetoclax, Homoharringtonine, Azacitidine Plus G-CSF for Newly Diagnosed AML (VHAG) (clinicaltrials.gov)
    P2, N=61, Not yet recruiting, First People's Hospital of Hangzhou
    New P2 trial
    |
    Venclexta (venetoclax) • azacitidine • Synribo (omacetaxine mepesuccinate)
    1m
    Gossypol suppresses tumorigenesis through inhibition of multiple deubiquitinating enzymes. (PubMed, Bioorg Chem)
    Moreover, Gossypol exhibited cytotoxic effects on human breast, prostate, and colorectal cancer cell lines, at least partially through downregulating the oncogenic substrates of targeted DUBs such as c-Myc, Mcl-1, MDM2, and Cyclin D1. Collectively, our findings position Gossypol as a promising small-molecule inhibitor targeting DUBs, especially USPs, and provide a rationale for further exploring its therapeutic potential in USP-driven cancers.
    Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • USP7 (Ubiquitin Specific Peptidase 7) • USP9X (Ubiquitin Specific Peptidase 9 X-Linked)
    |
    R-(-)-gossypol (AT 101)
    1m
    Efficacy and Safety of Lisafotoclax Plus Decitabine and Homoharringtonine in Venetoclax/Azacitidine Pretreated AML Patients (clinicaltrials.gov)
    P2, N=35, Not yet recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University
    New P2 trial
    |
    FLT3 (Fms-related tyrosine kinase 3) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • NPM1 (Nucleophosmin 1)
    |
    FLT3-ITD mutation • NPM1 mutation
    |
    Venclexta (venetoclax) • azacitidine • decitabine • Synribo (omacetaxine mepesuccinate)